|
|
Post by prcgorman2 on Jun 24, 2021 7:03:21 GMT -5
“we are flounder”, we are strong, and some of us are long!
$4 is the new floor. Stunning improvement from $1 from only a year or so ago. I’ve more than doubled my shares in the last 18 months, and twice added during the last two dips below $4. Nothing is certain, but thanks to hard work and UTHR it’s possible we’re on the way up and not looking back. (And all of that BS about Afrezza in this thread is worth less than the real thing). MNKD is a penny stock. If you’re invested, you’re a risk taker. Most of my investing is done for me by professionals, so this is my choice for a higher risk investment, and while I got in too early (2013), thanks to dollar cost averaging, it’s looking pretty sweet. Thank you Mike & team!!!
|
|
|
|
Post by dh4mizzou on Jun 24, 2021 7:59:55 GMT -5
How will this react if we get to $5.00? Will that open the stock up to new 'investors'? I'm thinking of funds now being able to purchase MNKD.
|
|
|
|
Post by uvula on Jun 24, 2021 8:30:55 GMT -5
How will this react if we get to $5.00? Will that open the stock up to new 'investors'? I'm thinking of funds now being able to purchase MNKD. You can search mnkd proboards for this identical question. We have hit $5 many times and dropped below $5 even more times. (Yes, I know, this time is different. And every time we hit $5 people say "this time is different.") |
|
|
|
Post by akemp3000 on Jun 24, 2021 9:05:12 GMT -5
Considering UTHR's CEO put up over $100M to accelerate the approval process, it's easy to recognize the optimism and anticipated approval of an improved delivery method for a drug that's been widely used for years and was recently approved by the FDA for a new indication. There's obviously no guarantee but this is probably as close as it gets. And yet we are flounder at less than $5 a share. The winds of change will soon be blowing hard. Yes. What's different about this moment in time from all those in the past is that good and consistent revenue is now within sight meaning later this year. This should change everything including pps, market perception, interest from funds, pipeline funding and more. Exciting time to be involved with this company. Oh, and not to mention a forthcoming announcement or two recently hinted. |
|
|
|
Post by sayhey24 on Jun 24, 2021 9:17:50 GMT -5
Here is the currently institutional ownership as last reported. investors.mannkindcorp.com/stock-information/ownership-profileBetween Blackrock, Statestreet and Vanguard it is near 20% ownership. Most funds can not buy in when its under $5, for some its $3. How long it needs to be above $5 varies but 30 days is a pretty good bet. Additionally since these three are current holders their ownership can be subject to fund rebalancing efforts. At this point things are looking pretty good for MNKD. With the Medtronic announcement even better. I wouldn't much worry about MNKD zipping through the 5's. I do have to laugh when I think about Medtronic. Here they base a good portion of their company on MiniMed between the pump and the CGM. At the time they could have had afrezza/TS for a song. Then Sayers blasts off with Dexcom and now UTHR partners with MNKD for TS. Soon MNKD will have the T1 kids approved and if Sports is right the moms are going to jump all over this which very well could affect pump sales. |
|
|
|
Post by cretin11 on Jun 24, 2021 9:48:54 GMT -5
How will this react if we get to $5.00? Will that open the stock up to new 'investors'? I'm thinking of funds now being able to purchase MNKD. You can search mnkd proboards for this identical question. We have hit $5 many times and dropped below $5 even more times. (Yes, I know, this time is different. And every time we hit $5 people say "this time is different.") This time is different! 😂😭😆 |
|
|
|
Post by prcgorman2 on Jun 24, 2021 13:20:22 GMT -5
Here is the currently institutional ownership as last reported. investors.mannkindcorp.com/stock-information/ownership-profileBetween Blackrock, Statestreet and Vanguard it is near 20% ownership. Most funds can not buy in when its under $5, for some its $3. How long it needs to be above $5 varies but 30 days is a pretty good bet. Additionally since these three are current holders their ownership can be subject to fund rebalancing efforts. At this point things are looking pretty good for MNKD. With the Medtronic announcement even better. I wouldn't much worry about MNKD zipping through the 5's. I do have to laugh when I think about Medtronic. Here they base a good portion of their company on MiniMed between the pump and the CGM. At the time they could have had afrezza/TS for a song. Then Sayers blasts off with Dexcom and now UTHR partners with MNKD for TS. Soon MNKD will have the T1 kids approved and if Sports is right the moms are going to jump all over this which very well could affect pump sales. NASDAQ report of instituional ownership for MNKD is just slightly less than 43%. If memory serves, that’s almost 2x from a year or two ago, and which probably help explain why we’re at $4.50 (ish) and not $1.50 (ish). ”This time” has been different. “This time” the increase in share price has been sustained. And we’re not yet cash flow break even. The folks making positive posts on this board are not responsible for the difference. It’s because of material improvements in business fundamentals. Money talks, BS walks. |
|
|
|
Post by mytakeonit on Jun 24, 2021 14:29:57 GMT -5
Yeah, hopefully Uvula walks ... and keeps walking till we're at $10 before he even thinks about buying MNKD shares.
I think $5 will be here by tomorrow and probably will be a low number soon thereafter.
But, that's mytakeonit
And, I'm still above Goldman Sachs
|
|
|
|
Post by sportsrancho on Jun 24, 2021 15:56:22 GMT -5
This time IS different:-)
Or maybe it’s similar to when Tom and I got in at $1.89 and rode it up to the Afrezza approval. ✨Double digits✨
|
|
|
|
Post by mytakeonit on Jun 24, 2021 16:16:41 GMT -5
And like I said before ... MNKD is not only about Afrezza. Double digits ... royalties !!!
But, that's mytakeonit
|
|
|
|
Post by neil36 on Jul 14, 2021 9:23:31 GMT -5
|
|
|
|
Post by peppy on Jul 14, 2021 9:32:20 GMT -5
I want to chuckle, and be a smart ass, as in, Was this petition originated in Tennessee? Asking for a friend. |
|
|
|
Post by harryx1 on Jul 14, 2021 9:34:48 GMT -5
|
|
|
|
Post by Chris-C on Jul 14, 2021 9:53:28 GMT -5
The soon to-be-losers who have been relentlessly shorting MNKD see a clear and present danger ahead. Perhaps the unnamed client is Martin Shkreli? Or his cousin Vladimir. It’s fascinating that they are not concerned about Tyvaso, per se, only the DPI version. This tells you everything you need to know. I’ll be especially impressed when they post the FDA’s reply. My guess is this “letter” is for Stocktwits readers only. |
|
|
|
Post by peppy on Jul 14, 2021 9:54:16 GMT -5
Short-acting bronchodilators Bronchodilators help open your airways to make breathing easier. Your doctor may prescribe short-acting bronchodilators for an emergency situation or for quick relief as needed. You take them using an inhaler or nebulizer. Examples of short-acting bronchodilators include:
albuterol (Proair HFA, Ventolin HFA) levalbuterol (Xopenex) ipratropium (Atrovent HFA) albuterol/ipratropium (Combivent Respimat) The corticosteroids that doctors most often prescribe for COPD are: Fluticasone (Flovent). This comes as an inhaler you use twice daily. Side effects can include headache, sore throat, voice changes, nausea, cold-like symptoms, and thrush. Budesonide (Pulmicort). This comes as a handheld inhaler or for use in a nebulizer. Side effects can include colds and thrush. Prednisolone. This comes as a pill, liquid, or shot. It’s usually given for emergency rescue treatment. Side effects can include headache, muscle weakness, upset stomach, and weight gain. MethylxanthinesFor some people with severe COPD, the typical first-line treatments, such as fast-acting bronchodilators and corticosteroids, don’t seem to help when used on their own. When this happens, some doctors prescribe a drug called theophylline along with a bronchodilator. Theophylline works as an anti-inflammatory drug and relaxes the muscles in the airways. It comes as a pill or liquid you take daily. The long-acting bronchodilators currently available are: aclidinium (Tudorza) arformoterol (Brovana) formoterol (Foradil, Perforomist) glycopyrrolate (Seebri Neohaler, Lonhala Magnair) indacaterol (Arcapta) olodaterol (Striverdi Respimat) revefenacin (Yupelri) salmeterol (Serevent) tiotropium (Spiriva) umeclidinium (Incruse Ellipta) Recommended LABA/LAMA combination bronchodilator therapies include: aclidinium/formoterol (Duaklir) glycopyrrolate/formoterol (Bevespi Aerosphere) tiotropium/olodaterol (Stiolto Respimat) umeclidinium/vilanterol (Anoro Ellipta) Combinations of an inhaled corticosteroid and a long-acting bronchodilator include: budesonide/formoterol (Symbicort) fluticasone/salmeterol (Advair) fluticasone/vilanterol (Breo Ellipta) ======================================================================================= It is probably superior.  |
|
